Manhattan Pharmaceuticals Completes Enrollment In Phase 2a Study Of Oral Oleoyl-estrone For Obesity
Thu, 22 Feb 2007 08:00 AM EST
... Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced it completed patient enrollment in its first Phase 2a multi-center, international clinical study evaluating the safety and preliminary efficacy of oral Oleoyl-estrone (OE) for the treatment of obesity. [click link for full article] ...
Related Topics
- Obesity
- Obesity and Overweight
- Overweight and Obesity
- Interferon Alfa-2a
- Peginterferon alfa-2a
- Oral Cancer
- Esterified Estrogens, Estrone, Estropipate Injection
- Dilation And Curettage
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Oral Health
- Amoxicillin Oral Suspension
- Zidovudine Oral Syrup
- Radiation Studies
- Obesity and Weight Management
- The Use of Acupuncture in Addiction and Obesity
- Shapedown Pediatric Obesity
- Obesity hypoventilation syndrome (OHS)
- Brain Injury
- Bismuth Subsalicylate Oral Liquid

Not Signed In -

